These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 17179736)
1. In vitro paclitaxel and radiation effects on the cell types responsible for vascular stenosis: a preliminary analysis. Zhang J; Melhem M; Kassing W; Kelly B; Wang Y; Krishnamoorthy M; Heffelfinger S; Desai P; Roy-Chaudhury P Blood Purif; 2007; 25(2):155-60. PubMed ID: 17179736 [TBL] [Abstract][Full Text] [Related]
2. Development of a local perivascular paclitaxel delivery system for hemodialysis vascular access dysfunction: polymer preparation and in vitro activity. Melhem M; Kelly B; Zhang J; Kasting G; Li J; Davis H; Heffelfinger S; Desai P; Roy-Chaudhury P Blood Purif; 2006; 24(3):289-98. PubMed ID: 16465049 [TBL] [Abstract][Full Text] [Related]
3. Arterial and venous smooth-muscle cells differ in their responses to antiproliferative drugs. Kim SJ; Masaki T; Leypoldt JK; Kamerath CD; Mohammad SF; Cheung AK J Lab Clin Med; 2004 Sep; 144(3):156-62. PubMed ID: 15454885 [TBL] [Abstract][Full Text] [Related]
4. Suppression of neointimal hyperplasia by sirolimus-eluting expanded polytetrafluoroethylene (ePTFE) haemodialysis grafts in comparison with paclitaxel-coated grafts. Baek I; Bai CZ; Hwang J; Park J; Park JS; Kim DJ Nephrol Dial Transplant; 2012 May; 27(5):1997-2004. PubMed ID: 22058173 [TBL] [Abstract][Full Text] [Related]
12. Protective role of clusterin/apolipoprotein J against neointimal hyperplasia via antiproliferative effect on vascular smooth muscle cells and cytoprotective effect on endothelial cells. Kim HJ; Yoo EK; Kim JY; Choi YK; Lee HJ; Kim JK; Jeoung NH; Lee KU; Park IS; Min BH; Park KG; Lee CH; Aronow BJ; Sata M; Lee IK Arterioscler Thromb Vasc Biol; 2009 Oct; 29(10):1558-64. PubMed ID: 19696405 [TBL] [Abstract][Full Text] [Related]
13. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery. Wessely R; Blaich B; Belaiba RS; Merl S; Görlach A; Kastrati A; Schömig A Thromb Haemost; 2007 Jun; 97(6):1003-12. PubMed ID: 17549304 [TBL] [Abstract][Full Text] [Related]
14. The range of optimal concentration and mechanisms of paclitaxel in radio-enhancement in gastrointestinal cancer cell lines. Toiyama Y; Inoue Y; Hiro J; Ojima E; Watanabe H; Narita Y; Hosono A; Miki C; Kusunoki M Cancer Chemother Pharmacol; 2007 May; 59(6):733-42. PubMed ID: 16957932 [TBL] [Abstract][Full Text] [Related]
15. Platelet-derived growth factor receptor antagonist STI571 (imatinib mesylate) inhibits human vascular smooth muscle proliferation and migration in vitro but not in vivo. Hacker TA; Griffin MO; Guttormsen B; Stoker S; Wolff MR J Invasive Cardiol; 2007 Jun; 19(6):269-74. PubMed ID: 17541129 [TBL] [Abstract][Full Text] [Related]
17. Stimulation of oestrogen receptor-expressing endothelial cells with oestrogen reduces proliferation of cocultured vascular smooth muscle cells. Odenlund M; Ekblad E; Nilsson BO Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):245-8. PubMed ID: 18290870 [TBL] [Abstract][Full Text] [Related]
18. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Aissat N; Le Tourneau C; Ghoul A; Serova M; Bieche I; Lokiec F; Raymond E; Faivre S Cancer Chemother Pharmacol; 2008 Jul; 62(2):305-13. PubMed ID: 17912526 [TBL] [Abstract][Full Text] [Related]